CERo Therapeutics Holdings (CERo Therapeutics Holdings) Interest Expense : $ Mil (TTM As of Dec. 2022)

View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. CERo Therapeutics Holdings's interest expense for the six months ended in Dec. 2022 was $ 0.00 Mil. CERo Therapeutics Holdings does not have enough years/quarters to calculate its interest expense for the trailing twelve months (TTM) ended in Dec. 2022.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. CERo Therapeutics Holdings's Operating Income for the six months ended in Dec. 2022 was $ -11.97 Mil. CERo Therapeutics Holdings's Interest Expense for the six months ended in Dec. 2022 was $ 0.00 Mil. GuruFocus does not calculate CERo Therapeutics Holdings's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

CERo Therapeutics Holdings Interest Expense Historical Data

The historical data trend for CERo Therapeutics Holdings's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Interest Expense Chart

CERo Therapeutics Holdings Annual Data

Trend

Dec21

Dec22

Interest Expense

CERo Therapeutics Holdings Semi-Annual Data
	Dec21	Dec22
Interest Expense	-	-

CERo Therapeutics Holdings Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

CERo Therapeutics Holdings (NAS:CERO) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

CERo Therapeutics Holdings's Interest Expense for the six months ended in Dec. 2022 was $0.00 Mil. Its Operating Income for the six months ended in Dec. 2022 was $-11.97 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2022 was $2.35 Mil.

CERo Therapeutics Holdings's Interest Coverage for the quarter that ended in Dec. 2022 is calculated as

GuruFocus does not calculate CERo Therapeutics Holdings's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. CERo Therapeutics Holdings Inc has enough cash to cover all of its debt. Its financial situation is stable.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080

Website

https://www.cero.bio

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines

From GuruFocus

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

By Business Wire • 03-07-2024